In both psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), a T2T TNF-blocker tapering strategy showed to be non-inferior to a T2T strategy.
Patients with intermediate-high- or high-risk renal cell carcinoma continued to benefit from pembrolizumab compared with placebo, updated results show.
We ask Ukrainian nurse Romanna Markiv about her life and the future she envisions, as well as the patient care she tirelessly provides in the city of Lviv.
Dr Tim O'Brien discusses tough medical experiences, while Dr Carlo Bravi argues why young urologists should learn open surgery, despite robotic surgery.
A study revealed that osteoarthritis is associated with a wide variety of diseases previously thought to be unrelated, such as anaemia and thromboembolic disease.
Prof. Fanos, addresses how COVID-19, AI, Big Data and the future of medicine may impact our relation with the microbiome.
Musculoskeletal disease patients manage moderate-to-vigorous physical training, but fail the recommended daily steps.
“À Chacun Son Everest!” organises trips that are of great inspiration for the children and women in remission joining; and for the physicians travelling with them.
Post-surgery hospital stay was much shorter for bladder cancer patients after full robotic radical cystectomy over those treated with open surgery.
According to a Spanish study, patients with rheumatoid arthritis and psoriatic arthritis have a markedly deteriorated sexual life compared with a healthy population.
Sarilumab demonstrated positive results in a phase 3 trial for PMR patients. More participants reached sustained remission and reduced flare risk.
The IL-17A/IL-17F blocker bimekizumab showed marked superiority in the primary and all ranked secondary endpoints of the phase 3 BE OPTIMAL trial as a PsA therapy.
A register study explored worldwide data on MACEs and venous thromboembolism associated with JAK inhibitors compared to anti-TNF agents in RA.
Prof. Dr. Reinhard Renneberg uses his own DNA as an example to show which migratory routes his earliest ancestors took.
A post-hoc trial analysis revealed nintedanib treatment benefit in patients with 4 characteristics associated with a fast decline in lung function.
A large register study in Denmark detected a substantially higher mortality risk for patients with rheumatoid arthritis (RA) who had comorbid depression.
Deucravacitinib showed convincing results as a treatment for patients with active systemic lupus erythematosus (SLE) in the phase 2 PAISLEY trial.
Cohort study data detected factors linked to a risk amplification for dementia development in patients with rheumatoid arthritis.
During the double-blind period of a withdrawal trial, baricitinib demonstrated predominance over placebo in the prevention of disease flares.
Once-daily therapy with upadacitinib led to an ASAS40 response in 45% of patients with active nr-axSpA at week 14 in the SELECT-AXIS-2 trial.